Cyproheptadine in the management of the galactorrhea-amenorrhea syndrome.
We evaluated long-term treatment with the antiserotonergic agent cyproheptadine in the management of the galactorrhea-amenorrhea syndrome. Fifteen women with a mean initial serum prolactin of 37 +/- 7 ng/mL received 16 to 24 mg of cyproheptadine daily; they had a significant decrease in prolactin concentration at 8 and at 16 weeks (P less than 0.01). Gonadotropin responses were variable, but no significant changes were recorded during treatment. Ten of the 15 women had menstrual bleeding while receiving cyproheptadine, seven had decreased galactorrhea, and two had cessation of galactorrhea. The side effects of treatment were transient drowsiness and weight gain. We conclude that long-term treatment of the galactorrhea-amenorrhea syndrome with cyproheptadine is effective in lowering serum prolactin in patients with mildly elevated or normal levels. Its effect on fertility remains to be ascertained.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D003533:Cyproheptadine / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D011247:Pregnancy; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D013577:Syndrome; D013997:Time Factors
D003533:Cyproheptadine; D011388:Prolactin